Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.
about
Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis.Rituximab for nephrotic syndrome in children.American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximabRituximab for troublesome cases of childhood nephrotic syndrome.The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysisRituximab Treatment for Nephrotic Syndrome in ChildrenNephrotic syndrome in children: from bench to treatmentSpectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohortA series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.Rituximab in children with resistant idiopathic nephrotic syndrome.IgM contributes to glomerular injury in FSGSAn unusual cause of severe persistent neutropenia in a child with nephrotic syndrome.Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.Adrenocorticotropic hormone analog use for podocytopathiesSingle dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndromeRituximab in idiopathic nephrotic syndrome: does it make sense?Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.Rituximab and minimal change nephrotic syndrome: a therapeutic option.Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.Update on the role of rituximab in kidney diseases and transplant.Rituximab in immunologic glomerular diseases.Colitis associated with biological agentsChildhood nephrotic syndrome--current and future therapies.Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.Indications for use and safety of rituximab in childhood renal diseases.Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO.Rituximab therapy in nephrotic syndrome: implications for patients' management.Is rituximab effective in childhood nephrotic syndrome? Yes and no.Steroid-resistant nephrotic syndrome: impact of genetic testing.B cell depletion: rituximab in glomerular disease and transplantationSecond-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience.Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.The glomerular permeability factors in idiopathic nephrotic syndrome.Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome.High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.Podocyte-actin dynamics in health and disease.
P2860
Q30240107-E3275397-B81E-40F8-A0B9-63A653CFB8F4Q33555088-AA4A9DF5-B66D-4B5D-8523-1260168D46F9Q33571864-D292F448-EA14-4938-8C36-17DC02D496FBQ34130591-F2D4C5E1-7A7B-4872-AE31-B4EE3658E889Q34683518-3E2B9C5D-9C71-45B1-93AB-8BC5F906CC82Q35040896-65E7A483-F033-4268-B589-AF4C1B2FAFB1Q35113681-659BA512-B465-487D-90CA-D3CB7D2FE97EQ35185376-4FFF880B-83A4-4817-8570-D4FB2560B36BQ35278415-17FF2CFD-D787-4F34-A066-5A74980CA8C2Q35674857-F273C23E-8AD1-4167-8AF3-4E580600BD99Q35982341-8FCA0D7A-13A7-47BD-BAF3-1E4EEA4DC57AQ36638347-E34E8A03-2E41-487A-B53C-BB1BF524C102Q36704943-0A0C09CE-108B-4808-B9DB-AE64BDDCC682Q36770915-50BCDF0C-5089-43AD-9142-908B1A4ACEFBQ37070458-E33C8756-FA4F-4E45-93F6-7FD39A831B53Q37108328-EB48D373-1D2B-44F0-83ED-DA2F154ECA76Q37275486-E93832AC-3B41-4208-B21B-FE59BB42DE56Q37375752-276830A8-2686-4843-9401-60EA0B23459CQ37728395-269841D4-F0AB-42C1-91CC-106C89D5A0B2Q37879578-41C218B2-39EE-42FA-BEFB-A2CF4BFC6FA0Q37928188-58AE2099-80C9-42DD-BC8E-1BCE1844352BQ37970443-18F466F3-119A-4528-A5BB-CF20E7E7D770Q37989298-9352F989-44C9-49D6-8DF9-47B8F01B3AC6Q38007938-75AB811C-2434-46A0-9335-99CC8581CC1AQ38017937-8A417D26-9263-4841-9C98-97EE5DA574C3Q38026511-61F86EC4-252D-441E-938F-3FDB6C567CF6Q38044851-937D351E-DA69-4B13-ACDE-7D8A3F4FDFBCQ38050959-C7984A04-837D-4B61-B65E-5CC8227FD9C7Q38075787-1DD48202-E8D4-43FD-A76A-598A703EF79FQ38118894-172F1D09-FF17-4726-9552-45F01D3A0EE2Q38177662-94BB5921-5919-44FE-8AF3-CDC09591BE5DQ38189360-6D6CF760-0369-472D-B117-8C51BFC60827Q38191615-B26A75C4-A7C6-48BB-ACA3-8BEE35E5D3EFQ38206050-8A094819-FAB1-4C94-8352-84323C9ABC77Q38449629-39D00564-B639-48DD-B703-425E5AF820C0Q38597096-24145DEA-C68B-450D-8373-4FDD958FAA3AQ38658597-C1499540-7FC2-4E02-956C-FCBEB3E5027CQ38679589-5B4022F6-7BA4-4945-A090-4E9F26934153Q38895019-420E3366-1ABE-4666-B7C5-AA78B72A54E9Q38940494-196E8CF3-9516-406D-BCB4-FE86A0809956
P2860
Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy and safety of treatme ...... syndrome: multicentric report.
@ast
Efficacy and safety of treatme ...... syndrome: multicentric report.
@en
Efficacy and safety of treatme ...... syndrome: multicentric report.
@nl
type
label
Efficacy and safety of treatme ...... syndrome: multicentric report.
@ast
Efficacy and safety of treatme ...... syndrome: multicentric report.
@en
Efficacy and safety of treatme ...... syndrome: multicentric report.
@nl
prefLabel
Efficacy and safety of treatme ...... syndrome: multicentric report.
@ast
Efficacy and safety of treatme ...... syndrome: multicentric report.
@en
Efficacy and safety of treatme ...... syndrome: multicentric report.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of treatme ...... syndrome: multicentric report.
@en
P2093
Aditi Sinha
Amit K Dinda
Arvind Bagga
Asha Moudgil
Ashima Gulati
Pankaj Hari
Rajendra N Srivastava
Sonika Sharma
Stanley C Jordan
P2860
P304
P356
10.2215/CJN.03470410
P577
2010-08-26T00:00:00Z